Tiziana Life Sciences Ltd (TLSA)
Automate Your Wheel Strategy on TLSA
With Tiblio's Option Bot, you can configure your own wheel strategy including TLSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLSA
- Rev/Share 0.0
- Book/Share 0.1575
- PB 9.2064
- Debt/Equity 0.0116
- CurrentRatio 1.7191
- ROIC -1.7392
- MktCap 86167700.0
- FreeCF/Share -0.1433
- PFCF -10.2923
- PE -6.596
- Debt/Assets 0.0064
- DivYield 0
- ROE -1.9551
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA
Published: December 29, 2025 by: Proactive Investors
Sentiment: Neutral
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has submitted its seventh annual Development Safety Update Report (DSUR) to the US Food and Drug Administration (FDA), reporting no drug-related serious adverse events associated with intranasal foralumab after a cumulative exposure of 37.4 patient-years. The DSUR covers the period from September 21, 2024, to September 2, 2025, and summarizes safety and tolerability data for intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed for neuroinflammatory diseases.
Read More
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
Published: December 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 97,687 common shares, bringing his total holding to 43,374,830 common shares, which is 36.08% of issued share capital.
Read More
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
Published: December 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Executive Chairman and Founder, Gabriele Cerrone will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York today.
Read More
Tiziana Life Sciences doses first patient in mid-stage Alzheimer's trial
Published: December 17, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial testing its intranasal drug candidate foralumab in patients with early Alzheimer's disease. The randomized, placebo-controlled study will evaluate foralumab as a standalone treatment and in combination with FDA-approved anti-amyloid drugs lecanemab (Leqembi) or donanemab in people with early or mild Alzheimer's, the company said.
Read More
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Published: December 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.
Read More
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer's trial next week
Published: December 12, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in early Alzheimer's disease, with the first patient expected to be dosed next week. The trial will study foralumab, a fully human anti-CD3 monoclonal antibody, as both a standalone therapy and in combination with the FDA-approved anti-amyloid drugs lecanemab or donanemab.
Read More
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial
Published: December 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer's clinical trial and plans to dose the first patient next week.
Read More
Tiziana Life Sciences plans spinout of IL-6 antibody program
Published: December 02, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed public company. Tiziana said its decision follows rising industry interest in the IL-6 pathway, highlighted by Novartis' $1.4 billion acquisition of Tourmaline Bio and its IL-6 inhibitor pacibekitug.
Read More
Tiziana Life Sciences' Phase 2 foralumab trial joins Healey ALS MyMatch Program
Published: November 25, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M Healey & AMG Center for ALS at Mass General Brigham. The study, supported by a grant from the ALS Association, will be led by Principal Investigators Suma Babu and James Berry at Mass General Brigham.
Read More
Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Positive
Tiziana Life Sciences' Foralumab intranasal anti-CD3 targets the Treg–microglia axis. However, their intranasal delivery makes them unique and patient-friendly. Foralumab has a Phase 2 for SPMS, a Phase 2a for MSA, and a Phase 2 for AD and ALS is planned. Early data show microglial PET reductions and stability in expanded access. Its bull case hinges on biomarkers against neuroinflammation.
Read More
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025.
Read More
Tiziana Life Sciences to showcase drug candidate at Saudi innovation forum
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh, underscoring Saudi Arabia's push to position itself as a global hub for life sciences research and investment. The Nasdaq-listed biotech will attend the Life Science Innovation Forum, a two-day event hosted Oct. 1–2 at the King Saud bin Abdulaziz University for Health Sciences Conference Center.
Read More
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Read More
Tiziana Life Sciences stock higher on inflammatory therapy plans
Published: September 25, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway. Tiziana noted that the therapy targets the interleukin-6 receptor, or IL-6R.
Read More
Tiziana to push ahead with second drug candidate in inflammation research
Published: September 25, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Thursday it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway, at a time when big drugmakers are paying closer attention to the area. The Boston-based biotech said the therap targets the interleukin-6 receptor, or IL-6R.
Read More
Tiziana to share trial design for nasal MS drug at global congress
Published: September 24, 2025 by: Proactive Investors
Sentiment: Neutral
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is set to highlight the design of its mid-stage trial for an experimental multiple sclerosis treatment at a leading international neurology conference this week. The biotechnology company said it will present a poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis, or ECTRIMS, being held Sept.
Read More
Tiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injury
Published: September 15, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been awarded a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). The grant will support a three-year study examining the therapy in the acute phase of SCI, focusing on patients who present immediately following injury.
Read More
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848.
Read More
Tiziana Life Sciences doses first MSA patient in new trial – ICYMI
Published: August 15, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system atrophy (MSA), a rare and fatal neurodegenerative condition with no approved treatment. Elrifi explained the trial involves the company's investigational monoclonal antibody, Foralumab, which is administered intranasally and aims to reduce neuroinflammation.
Read More
Tiziana Life Sciences doses first patient in Phase 2a MSA trial
Published: August 14, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA). The trial is being conducted at Brigham and Women's Hospital in Boston, Massachusetts.
Read More
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease.
Read More
Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment
Published: July 21, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding in the removal of harmful protein buildup linked to the disease. The company's lead drug, intranasal foralumab, is a fully human antibody designed to regulate the immune system.
Read More
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab.
Read More
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
Published: June 13, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Weill Cornell marks the fifth site participating in the trial, joining Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.
Read More
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.
Read More
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
Published: May 15, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's disease (AD), a newly published study has shown. The study, published in the Journal of Clinical Nuclear Medicine, was led by Dr Tarun Singhal and Dr Howard Weiner of Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.
Read More
Tiziana Life Sciences Announces Purchase of Shares by Chairman
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.
Read More
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
Published: May 09, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead drug candidate, intranasal foralumab, under an expanded access program. A PET scan revealed a significant decrease in microglial activation—an indicator of neuroinflammation linked to Alzheimer's progression—according to data presented by Dr Howard Weiner at the 2025 AD/PD Conference in Vienna.
Read More
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer's disease progression.
Read More
Tiziana shares surge 21% on promising multiple sclerosis data
Published: May 06, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralumab. The open-label study involved 10 patients with non-active secondary progressive MS, a form of the disease where disability progresses despite the absence of relapses and few treatment options exist.
Read More
About Tiziana Life Sciences Ltd (TLSA)
- IPO Date 2018-11-20
- Website https://www.tizianalifesciences.com
- Industry Biotechnology
- CEO Ivor R. Elrifi
- Employees 9